The Chemoimmunotherapy Era in CLL is Over

被引:0
作者
Thompson, Philip A. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
Chemotherapy; CLL; CHRONIC LYMPHOCYTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; OPEN-LABEL; PROGRESSION-FREE; FREE SURVIVAL; 17P DELETION; RITUXIMAB; CYCLOPHOSPHAMIDE; FLUDARABINE; VENETOCLAX;
D O I
10.1016/j.clml.2018.06.077
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
SA-S29-CLL
引用
收藏
页码:S116 / S119
页数:4
相关论文
共 32 条
[11]   First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial [J].
Eichhorst, Barbara ;
Fink, Anna-Maria ;
Bahlo, Jasmin ;
Busch, Raymonde ;
Kovacs, Gabor ;
Maurer, Christian ;
Lange, Elisabeth ;
Koeppler, Hubert ;
Kiehl, Michael ;
Soekler, Martin ;
Schlag, Rudolf ;
Vehling-Kaiser, Ursula ;
Koechling, Georg ;
Ploeger, Christoph ;
Gregor, Michael ;
Plesner, Torben ;
Trneny, Marek ;
Fischer, Kirsten ;
Doehner, Harmut ;
Kneba, Michael ;
Wendtner, Clemens-Martin ;
Klapper, Wolfram ;
Kreuzer, Karl-Anton ;
Stilgenbauer, Stephan ;
Boettcher, Sebastian ;
Hallek, Michael .
LANCET ONCOLOGY, 2016, 17 (07) :928-942
[12]   Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial [J].
Fischer, Kirsten ;
Bahlo, Jasmin ;
Fink, Anna Maria ;
Goede, Valentin ;
Herling, Carmen Diana ;
Cramer, Paula ;
Langerbeins, Petra ;
von Tresckow, Julia ;
Engelke, Anja ;
Maurer, Christian ;
Kovacs, Gabor ;
Herling, Marco ;
Tausch, Eugen ;
Kreuzer, Karl-Anton ;
Eichhorst, Barbara ;
Boettcher, Sebastian ;
Seymour, John F. ;
Ghia, Paolo ;
Marlton, Paula ;
Kneba, Michael ;
Wendtner, Clemens-Martin ;
Doehner, Hartmut ;
Stilgenbauer, Stephan ;
Hallek, Michael .
BLOOD, 2016, 127 (02) :208-215
[13]   Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia [J].
Furman, Richard R. ;
Sharman, Jeff P. ;
Coutre, Steven E. ;
Cheson, Bruce D. ;
Pagel, John M. ;
Hillmen, Peter ;
Barrientos, Jacqueline C. ;
Zelenetz, Andrew D. ;
Kipps, Thomas J. ;
Flinn, Ian ;
Ghia, Paolo ;
Eradat, Herbert ;
Ervin, Thomas ;
Lamanna, Nicole ;
Coiffier, Bertrand ;
Pettitt, Andrew R. ;
Ma, Shuo ;
Stilgenbauer, Stephan ;
Cramer, Paula ;
Aiello, Maria ;
Johnson, Dave M. ;
Miller, Langdon L. ;
Li, Daniel ;
Jahn, Thomas M. ;
Dansey, Roger D. ;
Hallek, Michael ;
O'Brien, Susan M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11) :997-1007
[14]   Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions [J].
Goede, Valentin ;
Fischer, Kirsten ;
Busch, Raymonde ;
Engelke, Anja ;
Eichhorst, Barbara ;
Wendtner, Clemens M. ;
Chagorova, Tatiana ;
de la Serna, Javier ;
Dilhuydy, Marie-Sarah ;
Illmer, Thomas ;
Opat, Stephen ;
Owen, Carolyn J. ;
Samoylova, Olga ;
Kreuzer, Karl-Anton ;
Stilgenbauer, Stephan ;
Doehner, Hartmut ;
Langerak, Anton W. ;
Ritgen, Matthias ;
Kneba, Michael ;
Asikanius, Elina ;
Humphrey, Kathryn ;
Wenger, Michael ;
Hallek, Michael .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (12) :1101-1110
[15]   Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial [J].
Hallek, M. ;
Fischer, K. ;
Fingerle-Rowson, G. ;
Fink, A. M. ;
Busch, R. ;
Mayer, J. ;
Hensel, M. ;
Hopfinger, G. ;
Hess, G. ;
von Gruenhagen, U. ;
Bergmann, M. ;
Catalano, J. ;
Zinzani, P. L. ;
Caligaris-Cappio, F. ;
Seymour, J. F. ;
Berrebi, A. ;
Jaeger, U. ;
Cazin, B. ;
Trneny, M. ;
Westermann, A. ;
Wendtner, C. M. ;
Eichhorst, B. F. ;
Staib, P. ;
Buehler, A. ;
Winkler, D. ;
Zenz, T. ;
Boettcher, S. ;
Ritgen, M. ;
Mendila, M. ;
Kneba, M. ;
Doehner, H. ;
Stilgenbauer, S. .
LANCET, 2010, 376 (9747) :1164-1174
[16]   Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study [J].
O'Brien, Susan ;
Jones, Jeffrey A. ;
Coutre, Steven E. ;
Mato, Anthony R. ;
Hillmen, Peter ;
Tam, Constantine ;
Osterborg, Anders ;
Siddiqi, Tanya ;
Thirman, Michael J. ;
Furman, Richard R. ;
Ilhan, Osman ;
Keating, Michael J. ;
Call, Timothy G. ;
Brown, Jennifer R. ;
Stevens-Brogan, Michelle ;
Li, Yunfeng ;
Clow, Fong ;
James, Danelle F. ;
Chu, Alvina D. ;
Hallek, Michael ;
Stilgenbauer, Stephan .
LANCET ONCOLOGY, 2016, 17 (10) :1409-1418
[17]   Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia [J].
Robak, Tadeusz ;
Dmoszynska, Anna ;
Solal-Celigny, Philippe ;
Warzocha, Krzysztof ;
Loscertales, Javier ;
Catalano, John ;
Afanasiev, Boris V. ;
Larratt, Loree ;
Geisler, Christian H. ;
Montillo, Marco ;
Zyuzgin, Ilya ;
Ganly, Peter S. ;
Dartigeas, Caroline ;
Rosta, Andras ;
Maurer, Joerg ;
Mendila, Myriam ;
Saville, M. Wayne ;
Valente, Nancy ;
Wenger, Michael K. ;
Moiseev, Sergey I. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) :1756-1765
[18]   Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia [J].
Roberts, Andrew W. ;
Davids, Matthew S. ;
Pagel, John M. ;
Kahl, Brad S. ;
Puvvada, Soham D. ;
Gerecitano, John F. ;
Kipps, Thomas J. ;
Anderson, Mary Ann ;
Brown, Jennifer R. ;
Gressick, Lori ;
Wong, Shekman ;
Dunbar, Martin ;
Zhu, Ming ;
Desai, Monali B. ;
Cerri, Elisa ;
Enschede, Sari Heitner ;
Humerickhouse, Rod A. ;
Wierda, William G. ;
Seymour, John F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) :311-322
[19]  
ROGERS KA, 2017, BLOOD S1, V130
[20]  
Rossi D, 2015, BLOOD